Vascular Ehlers-Danlos Syndrome - Pipeline Insight, 2019
This report can be delivered to the clients within 48 Hours
'Vascular Ehlers-Danlos Syndrome - Pipeline Insight, 2019' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vascular Ehlers-Danlos Syndrome pipeline landscape is provided which includes the disease overview and Vascular Ehlers-Danlos Syndrome treatment guidelines. The assessment part of the report embraces, in depth Vascular Ehlers-Danlos Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vascular Ehlers-Danlos Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Vascular Ehlers-Danlos Syndrome Understanding
Vascular Ehlers-Danlos Syndrome (vEDS), previously known as Ehlers-Danlos type IV), is a rare inherited connective tissue disorder that is caused by defects in a protein called collagen. It is generally considered the most severe form of Ehlers-Danlos Syndrome (EDS). Vascular EDS is usually caused by a change (mutation) in the COL3A1 gene. Rarely, it may be caused by a mutation in the COL1A1 gene. Inheritance is autosomal dominant. The signs and symptoms of vEDS vary but may include: Fragile tissues, Thin, translucent skin, Acrogeria, Pneumothorax. Common symptoms include thin, translucent skin; easy bruising; characteristic facial appearance; and fragile arteries, muscles and internal organs. vEDS is typically inherited in an autosomal dominant manner. vEDS is also associated with an increased risk of organ rupture, including tearing of the intestine and rupture of the uterus during pregnancy. It can cause serious and potentially life-threatening complications.
Vascular Ehlers-Danlos Syndrome Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Vascular Ehlers-Danlos Syndrome targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Vascular Ehlers-Danlos Syndrome pipeline report covers 2+ companies. Some of the key players include Acer Therapeutics (Celiprolol) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Vascular Ehlers-Danlos Syndrome Analytical Perspective by DelveInsight
SCOPE OF THE REPORT
'Vascular Ehlers-Danlos Syndrome - Pipeline Insight, 2019' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vascular Ehlers-Danlos Syndrome pipeline landscape is provided which includes the disease overview and Vascular Ehlers-Danlos Syndrome treatment guidelines. The assessment part of the report embraces, in depth Vascular Ehlers-Danlos Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vascular Ehlers-Danlos Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Vascular Ehlers-Danlos Syndrome Understanding
Vascular Ehlers-Danlos Syndrome (vEDS), previously known as Ehlers-Danlos type IV), is a rare inherited connective tissue disorder that is caused by defects in a protein called collagen. It is generally considered the most severe form of Ehlers-Danlos Syndrome (EDS). Vascular EDS is usually caused by a change (mutation) in the COL3A1 gene. Rarely, it may be caused by a mutation in the COL1A1 gene. Inheritance is autosomal dominant. The signs and symptoms of vEDS vary but may include: Fragile tissues, Thin, translucent skin, Acrogeria, Pneumothorax. Common symptoms include thin, translucent skin; easy bruising; characteristic facial appearance; and fragile arteries, muscles and internal organs. vEDS is typically inherited in an autosomal dominant manner. vEDS is also associated with an increased risk of organ rupture, including tearing of the intestine and rupture of the uterus during pregnancy. It can cause serious and potentially life-threatening complications.
Vascular Ehlers-Danlos Syndrome Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Vascular Ehlers-Danlos Syndrome targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Vascular Ehlers-Danlos Syndrome pipeline report covers 2+ companies. Some of the key players include Acer Therapeutics (Celiprolol) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Vascular Ehlers-Danlos Syndrome Analytical Perspective by DelveInsight
- In-depth Vascular Ehlers-Danlos Syndrome Commercial Assessment of products
- Vascular Ehlers-Danlos Syndrome Clinical Assessment of products
SCOPE OF THE REPORT
- The Vascular Ehlers-Danlos Syndrome report provides an overview of therapeutic pipeline activity for Vascular Ehlers-Danlos Syndrome across the complete product development cycle including all clinical and non-clinical stages
- It comprises of detailed profiles of Vascular Ehlers-Danlos Syndrome therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
- Detailed Vascular Ehlers-Danlos Syndrome Research and Development progress and trial details, results wherever available, are also included in the pipeline study
- Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Vascular Ehlers-Danlos Syndrome
- Establish a comprehensive understanding of the current pipeline scenario across Vascular Ehlers-Danlos Syndrome to formulate effective R&D strategies
- Assess challenges and opportunities that influence Vascular Ehlers-Danlos Syndrome R&D
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
- Get in detail information of each product with updated information on each project along with key milestones
- Devise Vascular Ehlers-Danlos Syndrome in licensing and out licensing strategies by identifying prospective partners with progressing projects for Vascular Ehlers-Danlos Syndrome to enhance and expand business potential and scope
- Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
1. REPORT INTRODUCTION
2. VASCULAR EHLERS-DANLOS SYNDROME (EHLERS-DANLOS TYPE IV)
2.1. Vascular Ehlers-Danlos Syndrome Disease Overview
2.2. Vascular Ehlers-Danlos Syndrome History
2.3. Vascular Ehlers-Danlos Syndrome Symptoms
2.4. Vascular Ehlers-Danlos Syndrome Causes
2.5. Vascular Ehlers-Danlos Syndrome Pathophysiology
2.6. Vascular Ehlers-Danlos Syndrome Diagnosis
2.6.1. Diagnostic Guidelines
3. VASCULAR EHLERS-DANLOS SYNDROME CURRENT TREATMENT PATTERNS
3.1. Treatment Guidelines
4. VASCULAR EHLERS-DANLOS SYNDROME- DELVEINSIGHT’S ANALYTICAL PERSPECTIVE
4.1. In-depth Commercial Assessment
4.1.1. Vascular Ehlers-Danlos Syndrome companies collaborations, Licensing, Acquisition –Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Vascular Ehlers-Danlos Syndrome Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Vascular Ehlers-Danlos Syndrome Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA
5. VASCULAR EHLERS-DANLOS SYNDROME PIPELINE THERAPEUTICS
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products
6. VASCULAR EHLERS-DANLOS SYNDROME-PRODUCTS ANALYSIS
6.1. Product Profiles
6.1.1. Celiprolol- Acer Therapeutics
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
7. RECENT TECHNOLOGIES
8. VASCULAR EHLERS-DANLOS SYNDROME KEY COMPANIES
8.1. Acer Therapeutics
8.2. Fibrocell Science
9. VASCULAR EHLERS-DANLOS SYNDROME KEY PRODUCTS
9.1. Celiprolol
9.2. Research programme: fibroblast autologous cell therapies
10. DORMANT AND DISCONTINUED PRODUCTS
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. VASCULAR EHLERS-DANLOS SYNDROME- UNMET NEEDS
12. VASCULAR EHLERS-DANLOS SYNDROME- FUTURE PERSPECTIVES
13. APPENDIX
14. REPORT METHODOLOGY
14.1. Secondary Research
14.2. Expert Panel Validation
2. VASCULAR EHLERS-DANLOS SYNDROME (EHLERS-DANLOS TYPE IV)
2.1. Vascular Ehlers-Danlos Syndrome Disease Overview
2.2. Vascular Ehlers-Danlos Syndrome History
2.3. Vascular Ehlers-Danlos Syndrome Symptoms
2.4. Vascular Ehlers-Danlos Syndrome Causes
2.5. Vascular Ehlers-Danlos Syndrome Pathophysiology
2.6. Vascular Ehlers-Danlos Syndrome Diagnosis
2.6.1. Diagnostic Guidelines
3. VASCULAR EHLERS-DANLOS SYNDROME CURRENT TREATMENT PATTERNS
3.1. Treatment Guidelines
4. VASCULAR EHLERS-DANLOS SYNDROME- DELVEINSIGHT’S ANALYTICAL PERSPECTIVE
4.1. In-depth Commercial Assessment
4.1.1. Vascular Ehlers-Danlos Syndrome companies collaborations, Licensing, Acquisition –Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Vascular Ehlers-Danlos Syndrome Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Vascular Ehlers-Danlos Syndrome Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA
5. VASCULAR EHLERS-DANLOS SYNDROME PIPELINE THERAPEUTICS
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products
6. VASCULAR EHLERS-DANLOS SYNDROME-PRODUCTS ANALYSIS
6.1. Product Profiles
6.1.1. Celiprolol- Acer Therapeutics
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
7. RECENT TECHNOLOGIES
8. VASCULAR EHLERS-DANLOS SYNDROME KEY COMPANIES
8.1. Acer Therapeutics
8.2. Fibrocell Science
9. VASCULAR EHLERS-DANLOS SYNDROME KEY PRODUCTS
9.1. Celiprolol
9.2. Research programme: fibroblast autologous cell therapies
10. DORMANT AND DISCONTINUED PRODUCTS
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. VASCULAR EHLERS-DANLOS SYNDROME- UNMET NEEDS
12. VASCULAR EHLERS-DANLOS SYNDROME- FUTURE PERSPECTIVES
13. APPENDIX
14. REPORT METHODOLOGY
14.1. Secondary Research
14.2. Expert Panel Validation
LIST OF TABLES
Table 1. Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Vascular Ehlers-Danlos Syndrome Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products
Table 1. Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Vascular Ehlers-Danlos Syndrome Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products
LIST OF FIGURES
Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Vascular Ehlers-Danlos Syndrome companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Vascular Ehlers-Danlos Syndrome Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs
KEY COMPANIES
Acer Therapeutics
Fibrocell Science
Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Vascular Ehlers-Danlos Syndrome companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Vascular Ehlers-Danlos Syndrome Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs
KEY COMPANIES
Acer Therapeutics
Fibrocell Science
